Regeneron Pharmaceuticals, Inc. $REGN Stock: Russell Investments Group Ltd. Cuts Stake

Russell Investments Group Ltd. trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 11.5% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 203,767 shares of the biopharmaceutical company’s stock after selling 26,384 shares during the period. Russell Investments Group Ltd.’s holdings in Regeneron Pharmaceuticals were worth $154,406,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of REGN. BlackRock Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $5,682,636,000. State Street Corp boosted its position in shares of Regeneron Pharmaceuticals by 3.6% during the second quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock worth $3,014,621,000 after buying an additional 170,210 shares during the period. Bank of America Corp DE boosted its position in shares of Regeneron Pharmaceuticals by 2.8% during the first quarter. Bank of America Corp DE now owns 1,189,584 shares of the biopharmaceutical company’s stock worth $919,120,000 after buying an additional 32,158 shares during the period. Amundi grew its holdings in Regeneron Pharmaceuticals by 27.5% in the 1st quarter. Amundi now owns 1,009,798 shares of the biopharmaceutical company’s stock worth $780,210,000 after buying an additional 217,892 shares in the last quarter. Finally, Legal & General Group Plc bought a new position in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $473,872,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $955.47 on Monday. The company has a market capitalization of $98.84 billion, a price-to-earnings ratio of 21.10, a price-to-earnings-growth ratio of 1.26 and a beta of 0.10. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.35 and a quick ratio of 2.89. Regeneron Pharmaceuticals, Inc. has a 1-year low of $591.52 and a 1-year high of $991.73. The business has a 50 day moving average price of $816.17 and a two-hundred day moving average price of $747.36.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last issued its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The firm had revenue of $5.12 billion during the quarter, compared to analyst estimates of $4.58 billion. During the same period last year, the company posted $11.83 EPS. The firm’s quarterly revenue was up 36.3% on a year-over-year basis. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 58.26 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Friday, November 20th will be paid a dividend of $0.94 per share. The ex-dividend date of this dividend is Friday, November 20th. This represents a $3.76 annualized dividend and a yield of 0.4%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.30%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, EVP Joseph Larosa sold 4,466 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $965.49, for a total transaction of $4,311,878.34. Following the transaction, the executive vice president directly owned 38,906 shares of the company’s stock, valued at $37,563,353.94. The trade was a 10.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Christine Poon sold 7,830 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $969.09, for a total value of $7,587,974.70. Following the transaction, the director directly owned 5,219 shares in the company, valued at approximately $5,057,680.71. The trade was a 60.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 27,028 shares of company stock valued at $25,025,950. Corporate insiders own 6.97% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on REGN. Raymond James Financial raised their target price on Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. Weiss Ratings upgraded Regeneron Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research report on Monday, November 2nd. Sanford C. Bernstein increased their price target on Regeneron Pharmaceuticals from $756.00 to $812.00 and gave the stock a “market perform” rating in a research note on Monday, November 2nd. Morgan Stanley raised their price target on Regeneron Pharmaceuticals from $779.00 to $855.00 and gave the company an “equal weight” rating in a report on Monday, November 2nd. Finally, TD Cowen lifted their price objective on shares of Regeneron Pharmaceuticals from $960.00 to $980.00 and gave the company a “buy” rating in a research note on Wednesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $898.97.

View Our Latest Stock Report on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Company Profile

(Free Report)

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

Further Reading

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.